Senior-led 510(k) consulting for medical device companies preparing, strengthening, or repositioning a premarket notification submission to the FDA.
Chosen for nearly two dozen FDA data-integrity audits.
Built for inspections, not just enrollment.
Decades guiding high‑stakes medtech and biotech programs.
The 510(k) is the most common premarket pathway to the U.S. market for medical devices, but clearance depends on more than filling out the right template.
Predicate selection, substantial equivalence rationale, and testing strategy all interact, and a misstep in any area can trigger a Refuse to Accept letter, an Additional Information request, or a Not Substantially Equivalent determination that derails the timeline and forces a fundamental rethink of the submission strategy.
Health Policy Associates (HPA) provides senior-led 510(k) consulting for sponsors who need a defensible submission strategy, not just a submission. Whether you’re preparing a 510(k), evaluating whether a De Novo is the better path, or recovering from FDA feedback that challenged your predicate or classification, we help you build a substantial equivalence case the FDA can follow, and your team can defend.
A 510(k) clearance comes down to one central question: is your device substantially equivalent to a legally marketed predicate?
We help sponsors build that case. We confirm that predicate selection is defensible, identify where evidence supports the comparison and where it falls short, and ensure the submission presents a clear, logical thread from device description through testing rationale to the substantial equivalence conclusion.
When the predicate landscape is thin or contested, we help you navigate the alternatives, including whether a De Novo classification or a Pre-Submission is the right next step.
The FDA recognizes three types of 510(k) premarket notifications, each designed for a different situation. We help sponsors determine which type fits their device and regulatory position, and then build or strengthen the submission accordingly.
The Traditional 510(k) is the standard submission type and the most widely used. It requires a full demonstration of substantial equivalence, including a complete device description, predicate comparison, performance testing data, biocompatibility information where applicable, and labeling. Most first-time submissions and devices entering a new product category follow this path.
We build the complete substantial equivalence case — from predicate selection and device comparison through performance data packaging — so the submission presents a clear, defensible argument the FDA can follow without requesting additional information.
The Special 510(k) is available when a manufacturer modifies its own legally marketed device and can demonstrate that the change does not affect intended use or alter the device’s fundamental technology. Because it relies on the manufacturer’s design control documentation rather than new performance testing, it typically receives a faster FDA review — but only if the modification and design control rationale are clearly presented.
We work with manufacturers to determine whether a Special 510(k) is appropriate for their modification and, when it is, to develop the design control summary and rationale demonstrating that the change does not alter the device’s fundamental technology or intended use.
The Abbreviated 510(k) allows sponsors to rely on FDA guidance documents, special controls, or recognized consensus standards to demonstrate substantial equivalence, rather than conducting a full device-to-predicate comparison for every performance characteristic. This pathway can streamline the submission when applicable standards exist, but the sponsor must clearly show conformance and explain how the standards address the device’s specific risks.
We identify which recognized standards and FDA guidance documents apply, structure the declaration of conformity, and address any gaps where the standards alone do not fully cover the device’s specific risk profile.
Not every device fits the 510(k) pathway. When no suitable predicate exists, a De Novo classification request may be the appropriate route for a novel device. And when a device falls into a 510(k)-exempt classification, the sponsor may not need to file a 510(k) at all — though the device must still meet all applicable general and special controls.
We evaluate both scenarios before a sponsor commits time and budget to the wrong submission type.
When we assess a device’s predicate landscape and find the comparison isn’t defensible, we help the team understand whether a De Novo, a Pre-Submission to clarify the FDA’s position, or a different regulatory strategy is the better path forward.
A 510(k) results in FDA clearance: a determination that your device is substantially equivalent to a legally marketed predicate. This is not the same as FDA approval, which is a more rigorous standard reserved for Class III devices going through the Premarket Approval (PMA) process.
The distinction shapes the evidence standard your submission must meet. A 510(k) does not require the FDA to independently determine that your device is safe and effective. Instead, the FDA evaluates whether your device is as safe and effective as the predicate you’ve chosen. That comparison, rather than a standalone safety and efficacy finding, is what drives the evidence requirements, testing strategy, and submission structure for your 510(k).
Understanding where your device falls on this spectrum is one of the first things we work through with sponsors, because a misunderstanding about the standard your submission must meet can lead to over-engineering the evidence package, under-preparing for the FDA’s actual questions, or pursuing the wrong pathway entirely.
When the stakes are high, HPA turns ambiguity into clear findings, prioritized risks and next steps, so your team stops debating in gray areas and starts moving with conviction.
HPA helps you make decisions and build evidence that holds up under FDA questioning—especially when data integrity, framing, or compliance concerns could derail your program.
Our senior-led team stays with you and manages scope changes transparently, so you avoid handoff drag, reduce rework, and control spend without the change-order spiral.
The scope of a 510(k) engagement depends on where the sponsor is in the submission process, what evidence is already in hand, and whether the FDA has weighed in.
Typical engagements include some or all of the following.
01
We evaluate your predicate landscape, confirm or adjust predicate selection, and develop the substantial equivalence rationale that ties your device description, intended use, and performance data into a coherent case.
When the predicate landscape is thin or contested, we help you determine whether a Pre-Submission is the right move to surface the FDA’s position before committing to a strategy that may not hold.
02
We draft and compile the 510(k) submission, ensuring the substantial equivalence argument is clear and consistent throughout. Where appropriate, we also review applicable FDA guidance and relevant regulations to support strategic decision-making.
Before finalizing, we screen for Refuse to Accept risks: the administrative deficiencies that cause the FDA to reject a 510(k) before substantive review begins. This includes verifying format compliance, completeness, and cross-section consistency so the submission clears the FDA’s acceptance checklist and moves directly into review.
03
We prepare your team for Pre-Submission meetings, develop question strategy and briefing content for Q-Sub interactions, and interpret the FDA’s written feedback so your team can act on it with confidence.
When the FDA issues an Additional Information request during 510(k) review, we help draft the response with the specificity and framing needed to resolve the question without reopening settled issues. We also provide executive summaries that explain submission status, regulatory risks, and next steps in clear business language for leadership, boards, and investors.
Some 510(k) programs need support beyond predicate strategy and submission preparation. When the product or program demands it, we can extend the engagement to include:
for sponsors recovering from an NSE determination, a challenged predicate, or a Refuse to Accept.
when the device includes a drug or biologic constituent part and the classification, lead-center determination, or quality system alignment under 21 CFR Part 4 must be resolved prior to submission.
including gap assessments against 21 CFR Part 820 (QMSR) and ISO 13485 requirements.
when the 510(k) pathway requires clinical data beyond bench testing and the sponsor needs help with study design, execution, or data analysis.
We scope these extensions based on your device’s specific needs and can connect the work directly to our Medical Device Regulatory Consulting, Clinical Trial Strategy & Execution, Quality Systems & Compliance Consulting, and FDA Combination Product Consulting services.
If your 510(k) work reveals the need for broader support, we can extend the engagement into further Regulatory Consulting or Clinical Trial Strategy & Execution services, so your submission and development efforts stay aligned.
A 510(k) clearance depends on the quality of your predicate strategy, the strength of your substantial equivalence case, and whether the submission holds together under FDA review.
When the predicate landscape is thin, the evidence has gaps, or a previous submission didn’t go as planned, the cost of getting it wrong isn’t just another review cycle. It’s lost time, lost budget, and lost confidence from leadership and investors.
HPA brings senior-led, audit-grade regulatory judgment to your program so you can submit with a defensible strategy and move toward clearance with a plan your team can stand behind.
